Aclaris Therapeutics, Inc. (ACRS): Price and Financial Metrics

Aclaris Therapeutics, Inc. (ACRS): $16.95

0.15 (+0.89%)

POWR Rating

Component Grades














  • ACRS scores best on the Growth dimension, with a Growth rank ahead of 54.6% of US stocks.
  • The strongest trend for ACRS is in Stability, which has been heading up over the past 179 days.
  • ACRS's current lowest rank is in the Value metric (where it is better than 6.76% of US stocks).

ACRS Stock Summary

  • For ACRS, its debt to operating expenses ratio is greater than that reported by merely 5.72% of US equities we're observing.
  • With a price/sales ratio of 161.77, Aclaris Therapeutics Inc has a higher such ratio than 98.32% of stocks in our set.
  • With a year-over-year growth in debt of -93.84%, Aclaris Therapeutics Inc's debt growth rate surpasses only 2.06% of about US stocks.
  • Stocks that are quantitatively similar to ACRS, based on their financial statements, market capitalization, and price volatility, are AKTS, EDIT, FREQ, TBPH, and SAGE.
  • ACRS's SEC filings can be seen here. And to visit Aclaris Therapeutics Inc's official web site, go to

ACRS Valuation Summary

  • In comparison to the median Healthcare stock, ACRS's price/earnings ratio is 138.36% lower, now standing at -14.
  • ACRS's price/sales ratio has moved NA NA over the prior 72 months.
  • ACRS's EV/EBIT ratio has moved down 1.9 over the prior 72 months.

Below are key valuation metrics over time for ACRS.

Stock Date P/S P/B P/E EV/EBIT
ACRS 2021-08-31 149.7 4.2 -14.0 -12.6
ACRS 2021-08-30 142.2 4.0 -13.3 -11.9
ACRS 2021-08-27 144.9 4.1 -13.6 -12.1
ACRS 2021-08-26 131.9 3.7 -12.4 -10.9
ACRS 2021-08-25 136.9 3.9 -12.8 -11.4
ACRS 2021-08-24 135.3 3.8 -12.7 -11.2

ACRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACRS has a Quality Grade of D, ranking ahead of 11.05% of graded US stocks.
  • ACRS's asset turnover comes in at 0.045 -- ranking 329th of 680 Pharmaceutical Products stocks.
  • IONS, INBP, and CYTK are the stocks whose asset turnover ratios are most correlated with ACRS.

The table below shows ACRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.045 0.255 -0.798
2021-03-31 0.070 0.261 -1.118
2020-12-31 0.080 0.208 -1.456
2020-09-30 0.068 0.187 -1.659
2020-06-30 0.050 0.184 -1.897
2020-03-31 0.065 0.377 -2.002

ACRS Price Target

For more insight on analysts targets of ACRS, see our ACRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $34.80 Average Broker Recommendation 1.25 (Strong Buy)

ACRS Stock Price Chart Interactive Chart >

Price chart for ACRS

ACRS Price/Volume Stats

Current price $16.95 52-week high $19.97
Prev. close $16.80 52-week low $9.26
Day low $16.70 Volume 351,446
Day high $17.05 Avg. volume 443,323
50-day MA $15.39 Dividend yield N/A
200-day MA $14.27 Market Cap 1.13B

Aclaris Therapeutics, Inc. (ACRS) Company Bio

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. The company was founded in 2012 and is based in Malvern, Pennsylvania.

ACRS Latest News Stream

Event/Time News Detail
Loading, please wait...

ACRS Latest Social Stream

Loading social stream, please wait...

View Full ACRS Social Stream

Latest ACRS News From Around the Web

Below are the latest news stories about Aclaris Therapeutics Inc that investors may wish to consider to help them evaluate ACRS as an investment opportunity.

Aclaris Therapeutics GAAP EPS of -$0.37 misses by $0.01, revenue of $1.5M misses by $0.3M

Aclaris Therapeutics press release (ACRS): Q4 GAAP EPS of -$0.37 misses by $0.01.Revenue of $1.5M (-5.1% Y/Y) misses by $0.3M.

Seeking Alpha | February 24, 2022

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -2.78% and 16.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2021 and provided a corporate update. “2021 was a tremendous year for the progression of our drug development pipeline, and I’m very proud of what our team has accomplished,” said Dr. Neal Walker, President & CEO

Yahoo | February 24, 2022

Aclaris Therapeutics Q4 2021 Earnings Preview (NASDAQ:ACRS)

Aclaris Therapeutics (NASDAQ:ACRS) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$0.36 and the consensus

Seeking Alpha | February 23, 2022

Those who invested in Aclaris Therapeutics (NASDAQ:ACRS) three years ago are up 97%

By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at...

Yahoo | February 21, 2022

Read More 'ACRS' Stories Here

ACRS Price Returns

1-mo 7.01%
3-mo 59.15%
6-mo 33.36%
1-year 12.18%
3-year 1,947.84%
5-year -32.42%
YTD 16.57%
2021 124.73%
2020 242.33%
2019 -74.42%
2018 -70.03%
2017 -9.14%

Continue Researching ACRS

Want to see what other sources are saying about Aclaris Therapeutics Inc's financials and stock price? Try the links below:

Aclaris Therapeutics Inc (ACRS) Stock Price | Nasdaq
Aclaris Therapeutics Inc (ACRS) Stock Quote, History and News - Yahoo Finance
Aclaris Therapeutics Inc (ACRS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5843 seconds.